Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Saved in:
| Title: | Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial. |
|---|---|
| Authors: | Selmaj KW; Center for Neurology, Łódź, Poland.; Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland., Steinman L; Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA., Comi G; Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy., Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Arnold DL; NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada., Hartung HP; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.; Brain and Mind Centre, The University of Sydney, Camperdown, NSW, Australia.; Department of Neurology, Medical University of Vienna, Vienna, Austria.; Department of Neurology, Palacký University Olomouc, Olomouc, Czech Republic., Montalbán X; Department of Neurology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain., Havrdová EK; Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty and General University Hospital, Prague, Czech Republic., Sheffield JK; Bristol Myers Squibb, Princeton, NJ, USA., Krakovich A; Bristol Myers Squibb, Princeton, NJ, USA., Cheng CY; Bristol Myers Squibb, Princeton, NJ, USA., Riolo JV; Bristol Myers Squibb, Princeton, NJ, USA., Pachai C; Bristol Myers Squibb, Princeton, NJ, USA., Thorpe A; Bristol Myers Squibb, Princeton, NJ, USA., DeBoer E; Bristol Myers Squibb, Princeton, NJ, USA., Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head Organs, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland., Cohen JA; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA., Cree BA; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2025 Nov; Vol. 31 (13), pp. 1557-1571. Date of Electronic Publication: 2025 Nov 05. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1477-0970 |
|---|---|
| DOI: | 10.1177/13524585251382796 |
